Solid Biosciences Inc (NASDAQ:SLDB) was down 10% during trading on Wednesday . The company traded as low as $5.23 and last traded at $5.69. Approximately 14,208 shares traded hands during trading, a decline of 95% from the average daily volume of 307,423 shares. The stock had previously closed at $6.32.

A number of equities research analysts have recently commented on SLDB shares. Goldman Sachs Group lowered Solid Biosciences from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $5.00 to $4.00 in a research report on Tuesday. Chardan Capital lowered Solid Biosciences from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $15.00 to $7.50 in a research report on Tuesday. Zacks Investment Research raised Solid Biosciences from a “hold” rating to a “buy” rating and set a $8.25 price target on the stock in a research report on Wednesday, February 13th. ValuEngine raised Solid Biosciences from a “hold” rating to a “buy” rating in a research report on Tuesday, March 19th. Finally, Credit Suisse Group lowered Solid Biosciences from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $7.00 to $6.00 in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company. Solid Biosciences presently has an average rating of “Hold” and a consensus price target of $20.11.

The company has a quick ratio of 10.31, a current ratio of 10.31 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $313.42 million, a PE ratio of -2.52 and a beta of 1.68.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.22). Equities analysts expect that Solid Biosciences Inc will post -2.53 EPS for the current fiscal year.

In related news, major shareholder Boxer Capital, Llc sold 450,000 shares of the stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $9.88, for a total transaction of $4,446,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Juan Andrey Zarur sold 8,000 shares of the stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $10.00, for a total value of $80,000.00. The disclosure for this sale can be found here. 31.20% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the stock. Jennison Associates LLC bought a new position in Solid Biosciences in the fourth quarter valued at approximately $21,109,000. Partner Fund Management L.P. grew its stake in Solid Biosciences by 66.9% in the fourth quarter. Partner Fund Management L.P. now owns 1,335,080 shares of the company’s stock valued at $35,780,000 after purchasing an additional 535,303 shares in the last quarter. BlackRock Inc. grew its stake in Solid Biosciences by 56.0% in the fourth quarter. BlackRock Inc. now owns 1,214,410 shares of the company’s stock valued at $32,546,000 after purchasing an additional 436,161 shares in the last quarter. Vanguard Group Inc grew its stake in Solid Biosciences by 82.0% in the third quarter. Vanguard Group Inc now owns 675,180 shares of the company’s stock valued at $31,855,000 after purchasing an additional 304,286 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Solid Biosciences by 82.0% in the third quarter. Vanguard Group Inc. now owns 675,180 shares of the company’s stock valued at $31,855,000 after purchasing an additional 304,286 shares in the last quarter. Institutional investors and hedge funds own 63.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Solid Biosciences (SLDB) Shares Down 10%” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/solid-biosciences-sldb-shares-down-10/3011349.html.

About Solid Biosciences (NASDAQ:SLDB)

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Recommended Story: What is Call Option Volume?

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.